Project Grant K23HL171822
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$193K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $542,402 in funding to support research conducted by the collaborative partnership between Henry Ford Health and Michigan State University Health Sciences. The goal of the project is to identify small molecules that can reverse profibrotic gene signatures in idiopathic pulmonary fibrosis (IPF), a devastating lung disease...
This federal Project Grant award for $595,286.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate a previously unappreciated mechanism of regulating collagen clearance in the lungs. The research seeks to delineate the pathways and upstream/downstream mechanisms governing a cellular homeostatic feedback loop that senses collagen synthesis and regulates its clearance. This work will use mouse...
This $5,715,866 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop novel, transformative therapies to substantially reduce the burden of pulmonary fibrosis (PF). The 5-year program will focus on investigating the early, pre-symptomatic progression of familial pulmonary fibrosis (FPF) to identify critical mechanisms driving disease initiation and progression. Key activities include: Analyzing...
This $651,019 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to elucidate the mechanisms behind dysfunctional epithelial repair processes that contribute to the development of pulmonary fibrosis. The research aims to identify factors driving aberrant epithelial cell states, determine the role of HIF signaling in preventing functional alveolar repair, and investigate niche-specific mechanisms regulating...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,546,880.00 to the University of Pittsburgh to conduct research on the regulation of myofibroblasts in idiopathic pulmonary fibrosis (IPF). The research aims to determine the "regulatory architecture" of open chromatin in myofibroblasts, evaluate how expression of E-box transcription factors regulates myofibroblast...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $695,403 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of Arizona to conduct research aimed at developing new therapeutic approaches to inhibit the progression of pulmonary fibrosis. The key objectives of the 4-year project are to: Determine whether restoring microvascular integrity through nanoparticle gene therapy can inhibit lung fibrogenesis. Define whether transplantation of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $797,845 to Vanderbilt University Medical Center (VUMC) to conduct research on reconceptualizing disease progression in pulmonary fibrosis (PF). The key objectives are to: 1) Develop and validate a Bayesian disease progression model to define the conserved, stage-specific progression of PF across physiological, anatomical, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), supports research to understand the role of alveolar epithelial cell stress signaling in the pathogenesis of pulmonary fibrosis. The award, made under the Cardiovascular Diseases Research Program (CFDA 93.837), totals $683,564 and is effective from July 1, 2025 through March 31, 2030. The research aims to elucidate how aberrant transitional alveolar type 2...
This $827,753 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop more effective gene-mapping methods for rare polygenic disorders like idiopathic pulmonary fibrosis (IPF). The project has three key objectives: (1) developing a network model-based association test informed by pleiotropy to gene expression traits, (2) creating a rare-variant association test accounting for genetic background using...
This $260,586 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development and optimization of a novel PET imaging probe to assess disease activity and progression in idiopathic pulmonary fibrosis (IPF). The principal investigator, Dr. Bernau, aims to optimize a probe called PEG-FUD that can detect early extracellular matrix deposition, a key feature of active IPF. The goals are to 1) improve the probe's imaging...